Sacral neuromodulation and intravesical botulinum toxin for refractory overactive bladder.

Area of Science:

• Urology
• Neuroscience
• Pharmacology

Background:

• Refractory overactive bladder (OAB) and urge urinary incontinence significantly impact quality of life.
• Current treatment options for OAB include behavioral therapies, oral medications, and invasive procedures.

Purpose of the Study:

• To review sacral neuromodulation (SNM) and intravesical botulinum toxin (BTX) injections for refractory OAB.
• To compare the efficacy, side effect profiles, and patient selection for these two treatment modalities.

Main Methods:

• Systematic review of existing literature on SNM and intravesical BTX for OAB.
• Analysis of reported efficacy rates, adverse events, and patient outcomes from clinical studies.

Main Results:

• SNM demonstrates high efficacy (50-90%) for OAB over a decade of use.
• Intravesical BTX offers a less invasive, though more transient, alternative with comparable efficacy.
• Distinct side effect profiles exist: BTX associated with elevated postvoid residuals and UTIs; SNM with pain and device issues.

Conclusions:

• Both intravesical BTX and SNM are effective treatments for OAB.
• Further research is necessary to establish treatment equivalence and identify optimal patient populations for each therapy.
• Investigating optimal dosing and predictive patient variables for BTX and SNM is crucial for improving outcomes and minimizing adverse events.